Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2017

View Archived Issues

AstraZeneca reviews key product and pipeline highlights of second quarter 2017

Daiichi Sankyo reflects on accomplishments of first quarter of fiscal 2017

CerSci Therapeutics obtains grant to support development of CT-044

Sanofi updates key developments of second quarter 2017

LAIV H5N2 vaccine demonstrates safety and long-lasting memory immune responses in healthy subjects

P2-VP8-P[8] subunit rotavirus vaccine shows safety and immunogenicity in toddlers and infants

Velusetrag improves symptoms in patients with gastroparesis in phase IIb study

Reduced tachyphylaxis seen in vivo with novel D1 receptor agonists

MRC announces two new partnerships with industry to speed drug discovery

Qu Biologics reports positive results from phase II study of QBECO

Helsinn and MEI Pharma begin phase III testing of pracinostat

IL-36 receptor identified as therapeutic target for IBD

Dosing begins in phase I study of Bolder Biotechnology's BBT-015

U.S. researchers patent EAAT2 activators

Bristol-Myers Squibb presents ROCK2 inhibitors

Kymab provides update on phase I study of KY-1005

Boehringer Ingelheim discloses BTK and IL-6 production inhibitors

RSV inhibitors identified by Enanta Pharmaceuticals

BioMarin to open additional phase III studies based on phase I/II data of BMN-270

FDA's arthritis advisory committee does not recommend approval of sirukumab for the treatment of RA

X4 Pharmaceuticals and Yale to work on genetic model of WHIM syndrome

FDA grants approval to ibrutinib for adult patients with chronic GvHD

Aclaris Therapeutics submits IND to FDA for ATI-50002

Proteostasis Therapeutics gives update on cystic fibrosis projects

IGF2BP3 found to be a novel target in thyroid cancer

Molecular Templates' merger with Threshold Pharmaceuticals completed

Takeda Pharmaceutical enters partnership with Cardurion Pharmaceuticals

Positive phase IIa results for GBR-830 as treatment of patients with atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...